What’s new in the Global Initiative for Asthma 2018 report and beyond
- 249 Downloads
The Global Initiative for Asthma (GINA) has regularly published and annually updated a global strategy for asthma management and prevention that has formed the basis for many national guidelines. The 2018 update of the GINA report incorporates new evidence following the routine twice-yearly cumulative review of the literature by the GINA Scientific Committee.
Recommendations in the 2018 edition were examined for new content and updates, and the scientific evidence behind these recommendations was examined and discussed. Focus was given to the management of asthma in adults in the general population and children more than 5 years of age. Selected new studies related to the management of asthma that may affect future recommendations were also discussed.
Results and discussion
There have been updates in the assessment of asthma, the role of fractional exhaled nitric oxide, and the stepwise treatment of asthma. Key messages from previous versions of the guidelines were also reiterated and updated with new evidence supporting previous recommendations. Changes and new recommendations may be expected in future editions based on new scientific evidence which has emerged in the recent months.
KeywordsAsthma Asthma guideline Asthma management and prevention Global Initiative for Asthma
Asthma-chronic obstructive pulmonary disease (COPD) overlap
Asthma and Macrolides: The Azithromycin Efficacy and Safety study
American Thoracic Society
Chronic obstructive pulmonary disease
European Respiratory Society
Food and Drug Administration
Fractional exhaled nitric oxide
Forced expiratory volume in 1 s
Forced vital capacity
Global Initiative for Asthma
Long-acting beta agonists
Long-acting muscarinic antagonist
Leukotriene receptor antagonists
National Asthma Education and Prevention Program
Number needed to treat
Peak expiratory flow
Randomized controlled trial
Short-acting beta agonist
The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens
Conflict of interest
K.Y. Ong declares that he has no competing interests.
- 3.Haselkorn T, Fish JE, Zeiger RS, Szefler SJ, Miller DP, Chipps BE, et al. Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol 2009;124:895–902.e1-4CrossRefGoogle Scholar
- 14.Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013; https://doi.org/10.1002/14651858.CD007313.pub3.CrossRefGoogle Scholar
- 16.Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev. 2010; https://doi.org/10.1002/14651858.CD005535.pub2.CrossRefGoogle Scholar